Sector
PharmaceuticalsOpen
₹1,286Prev. Close
₹1,293.85Turnover(Lac.)
₹9.02Day's High
₹1,310Day's Low
₹1,26352 Week's High
₹1,37552 Week's Low
₹815.8Book Value
₹389.21Face Value
₹10Mkt Cap (₹ Cr.)
573.62P/E
17.89EPS
72.65Divi. Yield
1.38Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 4.41 | 4.41 | 4.59 | 4.59 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 140.53 | 117.98 | 112.79 | 93.88 |
Net Worth | 144.94 | 122.39 | 117.38 | 98.47 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 123.98 | 109.29 | 118.89 | 114.67 |
yoy growth (%) | 13.43 | -8.07 | 3.67 | 11 |
Raw materials | -31.43 | -30.09 | -33.06 | -33.99 |
As % of sales | 25.35 | 27.53 | 27.81 | 29.64 |
Employee costs | -36.49 | -32.37 | -36.51 | -27.69 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 29.87 | 21.64 | 21.13 | 25.26 |
Depreciation | -1.89 | -2.03 | -2.29 | -1.5 |
Tax paid | -7.57 | -5.13 | -6.26 | -8.05 |
Working capital | -4.98 | -5.73 | 22.53 | -2.1 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 13.43 | -8.07 | 3.67 | 11 |
Op profit growth | 37.36 | 0.49 | -16.99 | 20.62 |
EBIT growth | 37.03 | 2.08 | -15.64 | 22.94 |
Net profit growth | 35.11 | 10.98 | -13.61 | 27.42 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.35 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493.2 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,483.15 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.4 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,167.95 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Company Sec. & Compli. Officer
Ashish R Shah
Chairman & Managing Director
Ashish U Bhuta
Whole Time Director & CFO
Dilip H Bhuta
Non-Exec. & Independent Dir.
Hina Ravindra Mehta
Independent Director
Sumit Ajaybhai Thakkar
Independent Director
KRISHNAN SUBHARAMAN
Independent Director
PANKAJ .
Nirmala Apartment P B No 37396,
93 Jayprakash Road Andheri(W),
Maharashtra - 400058
Tel: 91-22-66943121/67603603
Website: http://www.jenburkt.com
Email: investor@jenburkt.com
Office No 56-2,
Pinnacle Busine.Park, Mahakali Caves Road,
Mumbai - 400093
Tel: 91-22-62638200
Website: www.bigshareonline.com
Email: investor@bigshareonline.com
Summary
Jenburkt Pharmaceuticals Ltd, incorporated in 1985, was formed a venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family. The Company is engaged in manufacturing and mark...
Read More
Reports by Jenburkt Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.